CL2024001598A1 - Inhibidores de péptido del receptor de interleucina-23 - Google Patents

Inhibidores de péptido del receptor de interleucina-23

Info

Publication number
CL2024001598A1
CL2024001598A1 CL2024001598A CL2024001598A CL2024001598A1 CL 2024001598 A1 CL2024001598 A1 CL 2024001598A1 CL 2024001598 A CL2024001598 A CL 2024001598A CL 2024001598 A CL2024001598 A CL 2024001598A CL 2024001598 A1 CL2024001598 A1 CL 2024001598A1
Authority
CL
Chile
Prior art keywords
interleukin
peptide inhibitors
receptor peptide
compounds
diseases
Prior art date
Application number
CL2024001598A
Other languages
English (en)
Spanish (es)
Inventor
Fischer Munch Henrik
Bjerre HOLM Niels
Leth Rasmus
Due Larsen Bjarne
Mosolff Mathiesen Jesper
Caldararu Octav
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of CL2024001598A1 publication Critical patent/CL2024001598A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CL2024001598A 2021-12-01 2024-05-28 Inhibidores de péptido del receptor de interleucina-23 CL2024001598A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21211815 2021-12-01

Publications (1)

Publication Number Publication Date
CL2024001598A1 true CL2024001598A1 (es) 2024-11-15

Family

ID=78821013

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001598A CL2024001598A1 (es) 2021-12-01 2024-05-28 Inhibidores de péptido del receptor de interleucina-23

Country Status (12)

Country Link
US (1) US20250154198A1 (https=)
EP (1) EP4440592A1 (https=)
JP (1) JP2024543204A (https=)
KR (1) KR20240111800A (https=)
CN (1) CN118354781A (https=)
AU (1) AU2022402440A1 (https=)
CA (1) CA3240982A1 (https=)
CL (1) CL2024001598A1 (https=)
IL (1) IL313185A (https=)
MX (1) MX2024006556A (https=)
TW (1) TW202332682A (https=)
WO (1) WO2023099669A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) * 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121794283A (zh) * 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
MX384213B (es) 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2018089693A2 (en) 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
WO2018136646A1 (en) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021007433A1 (en) 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021209086A1 (en) * 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146458A1 (en) 2020-01-15 2021-07-22 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Also Published As

Publication number Publication date
IL313185A (en) 2024-07-01
MX2024006556A (es) 2024-06-12
TW202332682A (zh) 2023-08-16
WO2023099669A1 (en) 2023-06-08
CA3240982A1 (en) 2023-06-08
US20250154198A1 (en) 2025-05-15
AU2022402440A1 (en) 2024-05-30
CN118354781A (zh) 2024-07-16
KR20240111800A (ko) 2024-07-17
JP2024543204A (ja) 2024-11-19
EP4440592A1 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
CL2024001598A1 (es) Inhibidores de péptido del receptor de interleucina-23
MA58170B1 (fr) Dérivés carboxy avec des proprietes anti-inflammatoires
UY27627A1 (es) Aza - arilpiperazinas
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
EA201890618A1 (ru) Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
Tan et al. The inhibition of Cdk5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
AR070561A1 (es) Anillos intravaginales monoliticos que comprenden progesterona y metodos para su fabricacion y uso
EP3999121A4 (en) Treatment/prevention of disease by linc complex inhibition
JOP20230186A1 (ar) أجسام مضادة لـ cd30l واستخداماتها
CR10387A (es) Derivados de 6,7,8,9-tetrahidro-5h-pirimido[4,5-d]azepin-4-il] amina como moduladores del potencial transitorio de receptor vaillinoide 1 para el tratamiento de dolor
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
MX2022008265A (es) Compuestos y metodos para el tratamiento del dolor visceral.
Petrelli et al. Poly (ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against ischemic stroke in mice
Zhou et al. Design and synthesis of nanofibers of self-assembled de novo glycoconjugates towards mucosal lining restoration and anti-inflammatory drug delivery
EP3440045A4 (en) PREVENTING, TREATING AND REVERSING DISEASES USING THERAPEUTICALLY ACTIVE AMOUNTS OF DICARBONIC ACID COMPOUNDS
EP2231148A4 (en) Pharmaceutical composition for the treatment and prevention of heart disease
PH12018502703A1 (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
CL2024001843A1 (es) Compuestos
MX2024015497A (es) Nuevos peptidos como antagonistas selectivos del receptor de la il-23
MX2025014147A (es) Inhibidores peptidicos del receptor de interleuquina-23
MX2025013287A (es) Inhibidores peptidicos del receptor de interleucina-23
EA201791686A1 (ru) Клизма для ректального введения
JOP20230253A1 (ar) مركبات بيريدو بيريميدين واستخداماتها لعلاج مرض تكاثري